What was a notable DAPT length for patients treated in the POEM trial?

• A. 1 month
• B. 3 months
• C. 6 months
• D. 12 months

Answer: (A)

The notable duration of dual antiplatelet therapy (DAPT) for patients treated in the POEM trial is 1 month. This trial specifically evaluated the safety and efficacy of DAPT for an abbreviated period following certain procedures, such as percutaneous coronary intervention (PCI) typically involving drug-eluting stents.

The choice of a 1-month duration is significant in a clinical context as it suggests that this shortened period may be adequate for achieving optimal outcomes while potentially minimizing the risks associated with prolonged antiplatelet therapy, such as bleeding complications.

In comparison to other common DAPT durations, such as 3, 6, or 12 months, the POEM trial presents evidence for a shorter approach tailored for specific patient populations and treatment settings. This has important implications for clinical practice, as it challenges traditional perceptions regarding the necessary length of DAPT post-intervention.

Understanding the POEM trial findings aids healthcare professionals in making informed decisions about the duration of DAPT based on individual patient risk factors and the specific clinical scenarios they encounter.